Surface Oncology to Present at 2018 UBS Global Healthcare Conference
CAMBRIDGE, Mass., May 15, 2018 (GLOBE NEWSWIRE) -- Surface Oncology (NASDAQ:SURF), a clinical-stage immuno-oncology company developing next-generation immunotherapies that target the tumor microenvironment, today announced that Chief Executive Officer Jeff Goater will present a company overview at the 2018 UBS Global Healthcare Conference in New York, NY on Monday, May 21 at 9:00 a.m. eastern time.
A live webcast of the presentation will be accessible through Surface Oncology’s Investor Relations website at investors.surfaceoncology.com. A replay of the webcast will be archived on Surface Oncology’s website for 30 days following the presentation.
ABOUT SURFACE ONCOLOGY
Surface Oncology is an immuno-oncology company developing next-generation antibody therapies focused on the tumor microenvironment with lead programs targeting CD47, CD73, CD39 and IL-27. Surface’s novel cancer immunotherapies are designed to achieve a clinically meaningful and sustained anti-tumor response and may be used alone or in combination with other therapies. The company has a pipeline of seven novel immunotherapies and a strategic collaboration with Novartis focused on up to three next-generation cancer immunotherapies. For more information, please visit www.surfaceoncology.com.
Media Contact:Paul Goldsmith, Ten Bridge Communications Paul@Tenbridgecommunications.com 617-697-3479
Investor Contact: Jessica Fees JFees@surfaceoncology.com 617-714-4096